EC approves AstraZeneca’s Tagrisso with chemotherapy for EGFR-mutated lung cancer
AstraZeneca has received approval from the European Commission (EC) to use its cancer drug, Tagrisso (osimertinib), in combination with pemetrexed and platinum-based chemotherapy as a first-line treatment for adult patients with advanced epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC). This approval is specifically for patients whose tumors exhibit exon 19 deletions or […]